David M. Kornhauser, Craig W. Hendrix, Lynda J. Nerhood, Brent G. Petty, Amina S. Woods, John G. Bartlett, Paul S Lietman

Research output: Contribution to journalArticlepeer-review

76 Scopus citations


The effects of probenecid, a known inhibitor of glucuronidation, on the pharmacokinetics of zidovudine were assessed in eight subjects receiving zidovudine as treatment for human immunodeficiency virus infection. Zidovudine plasma concentrations were measured while subjects were receiving zidovudine alone, after 3 days of zidovudine plus 500 mg probenecid every 8 h, and after 3 days of zidovudine plus 500 mg probenecid plus 260 mg quinine sulphate every 8 h. A median increase of 80% in the area under the zidovudine plasma concentration/time curve occurred with the addition of probenecid. Quinine sulphate prevented the probenecid effect but had no effect on zidovudine kinetics when taken without probenecid by four other subjects. All of the effects were secondary to changes in zidovudine metabolism, since neither probenecid nor quinine changed the renal elimination of zidovudine. Probenecid could be used in combination with zidovudine to extend the interval between doses and reduce the daily requirement for zidovudine, thus enhancing convenience and reducing costs.

Original languageEnglish (US)
Pages (from-to)473-475
Number of pages3
JournalThe Lancet
Issue number8661
StatePublished - Aug 26 1989

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'PROBENECID AND ZIDOVUDINE METABOLISM'. Together they form a unique fingerprint.

Cite this